Author:Soumyopriyo Saha, Senior Director, Life Science – AI and Analytics, TCG Digital
Publications
If you would like to receive a full-text copy of any of the content listed below, email ma@admabio.com.
To expedite your request, please include the title of the content, your first and last name, healthcare designation (MD, NP, etc.) and business address.
Clinical & Real-World Data
Case Study: IgG deficient patient receiving immune globulin intravenous, human-slra 10% demonstrates improvement in quality of life
Authors:C Miller, B Prosser, D Blake, D Doyle
Poster presented at: Clinical Immunology Society 2024 Annual Meeting; May 1-4, 2024; Minneapolis, MN.
Retrospective Review of Real-World Evidence of Immune Globulin Intravenous (IVIG), Human-slra 10% in Patients with Primary Immunodeficiency with Recurrent Infections
Authors:Myers G, Huss J, McNeil D, Melton S, Anaya M, Simard MC
Poster presented at: Consortium of Independent Immunology Clinics Spring 2024 Meeting; April 13, 2023; Arlington, TX.
Immune Response to Respiratory Viruses and Respiratory Viral Infections in Susceptible Populations
Authors:Fragkou PC, Chemaly R, De Angelis G, Dimopoulou D, Menchinelli G, Skevaki C
Published: Front Med. 10:1330265.
Clinical Assessment of Safety, Pharmacokinetics, and Efficacy of Immune Globulin Intravenous 10% in Pediatric Patients
Authors:Melamed I, Walter J, Alpan O, Jhaveri D, Koterba A, Leiding J
Poster presented at: American College of Allergy, Asthma, and Immunology 2023 Annual Scientific Meeting; November 9-13, 2023; Anaheim, CA.
Immune Globulin Intravenous (Human) 10% Liquid is Safe and Efficacious in Pediatric Patients with Primary Immune Deficiency Disorders
Authors:Melamed I, Walter J, Alpan O, Jhaveri D, Koterba A, Leiding J
Poster presented at: IgNS 2023 National Conference; October 5-8, 2023; Denver, CO.
Case Report: ASCENIV Use in Three Young Children with Immune Abnormalities and Acute Respiratory Failure Secondary to RSV Infection
Authors:Bindernagel C, Sotoudeh S, Nguyen M, Wetzstein G, Sriaroon P, Walter J
Published: Front Immunol. 2023;14:1154448
Response to Asceniv Treatment in a Case Series of Patients with Antibody Deficiency and Related Infections Refractory to Conventional Immunoglobulin Replacement Therapy
Authors:Tambay A, Loop L, Siri D, Geng B
Poster presented at: Aspen 2023 Annual Allergy Conference; July 30 - August 3, 2023; Aspen, CO.
In-vivo and Human Evidence for Potential Efficacy of Therapeutic Polyclonal RSV Neutralizing Antibodies for Palivizumab-resistant RSV Infections
Authors:Ramirez KA, Mond J, Papenburg J, Boivin G, Gilbert BE, Falsey AR, Bagga B, DeVincenzo JP
Published: Virology. 2023; 586:115-121
Case Report of Real-World Use of human-slra 10% through Subcutaneous Infusion
Authors:Loop L, Geng B
Poster presented at: The European Academy of Allergy and Clinical Immunology (EAACI) Congress; June 9-11, 2023; Hamburg, Germany
Treatment Response to Unique Blend IVIG with High Titers to RSV and Common Respiratory Pathogens in Patients with Antibody Deficiency and Chronic Lung Disease
Authors:Loop L, Tambay A, Geng B
Poster presented at: The European Academy of Allergy and Clinical Immunology (EAACI) Congress; June 9-11, 2023; Hamburg, Germany
Reductions in Infections and Associated Complications in Nine Common Variable Immunodeficiency Patients Treated with Immune globulin intravenous, human-slra
Authors:Huss J, McNeil D, Melton S, Myers G
Published: Poster presented at: The Eastern Allergy Conference Annual Meeting; June 1-4, 2023; Palm Beach, FL
Case Study: Successful Transition to ASCENIV Therapy with Improved PROMs
Authors:Prosser B, Miller C
Poster presented at: CIS 2023 Annual Meeting; May 18-21, 2023; St Louis, MO
Case Study: Successful Transition to ASCENIV Therapy with Improved PROMs
Authors:Prosser B, Miller C, Walton T
Published: Clin Immunol. 2023;250(Supp):109445
ASCENIV™ utilization in a primary immunodeficiency patient with recurrent viral infections
Authors:Rosenbach KP, Greener BN, Rosenbach JT, Wetzstein GA
Published: Immunol Med. 2023;46(1):58-60
Treatment with intravenous immune globulin 10% in a real-world outpatient setting
Authors:Herrscher R, Rosenbach K, Luu Q, Kim-Romo D, Van Anglen L
Poster presented at: AAAAI 2023 Annual Meeting; February 24-27, 2023; San Antonio, TX
Real-world utilization of immune globulin intravenous 10% at physician office infusion centers
Authors:Herrscher R , Luu Q, Kim-Romo D, Van Anglen L
Poster presented at: ACAAI 2022 Annual Scientific Meeting; November 10-14, 2022; Louisville, KY
Real-world evaluation of immune globulin intravenous 10% in the treatment of primary immunodeficiency
Authors:Van Anglen L, Kim-Romo D
Poster presented at: IgNS 2022 11th National Conference; September 29-October 2, 2022; Washington, DC
Review of ASCENIV in Two Young Males with Immune Abnormalities and RSV-Induced Respiratory Failure: A Case Series
Authors:Bindernagel C, Sullivan S, Miranda MA, Timothy P, Wetzstein G, Sriaroon P, Walter J
Poster presented at: The Florida Allergy, Asthma & Immunology Society (FAAIS) 2022 Annual Meeting; July 15-17, 2022; Orlando, FL
ASCENIV™ reduces viral infections and associated comorbidities in a primary immunodeficiency patient
Authors:Rosenbach K, Greener B, Rosenbach J, Wetzstein G
Poster presented at: CIS 2022 Annual Meeting; March 31-April 3, 2022; Charlotte, NC
Use of ASCENIV™ in a young male with immune abnormalities and multiviral-induced respiratory failure
Authors:Bindernagel C, Sullivan S, Miranda MA, Timothy P, Wetzstein G, Sriaroon P, Walter, J
Poster presented at: AAAAI 2022 Annual Meeting; February 25-28, 2022; Phoenix, AZ
Clinical impact of concomitant use of a novel high-titer immune globulin in an adult with COVID-19 and severe acute respiratory distress syndrome (ARDS)
Authors:Wetzstein GA, Ismail M, Gruenglas J, Decker D, Mond J
Poster presented at: 2021 International Society for Influenza and Other Respiratory Virus Diseases—World Health Organization (ISIRV-WHO) Virtual Conference; October 19-21, 2021
Kinetics of post-vaccination seroprotection to S. pneumoniae for the immune-compromised and vaccine-naïve populations
Authors:Mond J, Scobie M, Tolman C, Gruenglas J, Martinez J
Poster presented at: IDWeek 2021 Virtual Conference; September 29-October 3, 2021
RI-002, an intravenous immunoglobulin containing high titer neutralizing antibody to RSV and other respiratory viruses for use in primary immunodeficiency disease and other immune compromised populations
Authors:Wasserman RL, Greener BN, Mond J
Published: Expert Rev Clin Immunol. 2017;13(12):1107-1119
Efficacy, safety, and pharmacokinetics of a new 10% liquid intravenous immunoglobulin containing high titer neutralizing antibody to RSV and other respiratory viruses in subjects with primary immunodeficiency disease
Authors:Wasserman RL, Lumry W, Harris J III, Levy R, Stein M, Forbes L, Cunningham-Rundles C, Melamed I, Kobayashi A, Du W, Kobayashi R
Phase 3 study published: J Clin Immunol. 2016;36(6):590-599
Analysis of specific antibody levels in PIDD patients enrolled in a pivotal trial with an IVIG containing high titer neutralizing antibody to RSV
Authors:Mond J, Orange J, Du W, Kobayashi A, Kobayashi R, Cunningham-Rundles C, Lumry W, Harris J III, Levy R, Stein M, Forbes L, Melamed I, Kestenberg K, Wasserman RL
Poster presented at: CIS 2015 Annual Meeting Immune Deficiency & Dysregulation North American Conference; April 9-12, 2015; Houston, TX
Authors:
Published:
Preclinical Data
Treatment with novel RSV Ig RI-002 controls viral replication and reduces pulmonary damage in immunocompromised Sigmodon hispidus
Authors:Boukhvalova M, Blanco JCG, Falsey AR, Mond J
Published: Bone Marrow Transplant. 2016;51(1):119-126
Therapeutic immunoglobulin selected for high antibody titer to RSV also contains high antibody titers to other respiratory viruses
Authors:Orange JS, Du W, Falsey AR
Published: Front Immunol. 2015;6:431
Compassionate Use
Treatment of RSV lower respiratory tract infection in two immunocompromised children with polyclonal immunoglobulin containing standardized levels of neutralizing anti-RSV antibodies
Authors:Levy ER, Madigan T, Binnicker MJ, Mond J, Huskins WC
Poster presented at: IDWeek; October 5, 2019; Washington, DC
Compassionate use experience with high-titer respiratory syncytical virus (RSV) immunoglobulin in RSV-infected immunocompromised persons
Authors:Falsey AR, Koval C, DeVincenzo JP, Walsh EE
Published: Transpl Infect Dis. 2017;19(2):10.1111/tid.12657
IVIG Manufacturing Overview
Gloveless Robotic Isolator Technology: Mitigating Biopharma Industry's Implicit Biases on Contamination Control from an Early Adopter of Advanced Aseptic Technology
Authors:McCall J, Gruenglas J
Published: Sixth International Conference on PharmScience Research & Development; February 26-28, 2024; Boston, MA
Manufacturing process optimization of ADMA Biologics’ intravenous immunoglobulin products, BIVIGAM® and ASCENIV™
Authors:Wasserman RL, Garcia D, Greener BN, Kestenberg K, Pinkert A, Mond J, Grossman A
Published: Immunotherapy. 2019 Nov;11(16):1423-1433
Health Policy
Acute Hepatitis B Infection: U.S. Policy and Guidelines
Authors:Henin S, Gruenglas J, Anaya M, Simard M-C
Published: In: Feitelson M, ed. Hepatitis B Virus – Pathogenesis and Therapeutic Approaches. IntechOpen; 2024;. doi: 10.5772/intechopen.1005754
All IG Products Are Not the Same!
Author:Siegel J
Published: Pharmacy Practice News, February 2024
Ethical assessment of post-exposure prophylaxis
Authors:Gruenglas J, Mond J
Published: The Journal of Healthcare Ethics and Administration. 2021 Aug 12; 29:37
Health Economics and Outcomes Research
Access to Intravenous Immune Globulin and Patient Compliance: Follow-up Results from an IVIG Support Program
Authors:Gruenglas J, Anaya M, Carneiro R
Poster presented at: National Home Infusion Association (NHIA) 2024; March 23-27, 2024; Austin, TX
Pharmacoeconomic analysis of a unique immune globulin containing a blend of high-titer RSV and normal source plasma compared with IVIG+palivizumab in a patient with SCID
Authors:Gruenglas J, Miller R, Wetzstein G, Carneiro R
Poster presented at: Fifth International Conference on PharmScience Research & Development; February 21-24, 2023; Las Vegas, NV
Patient support facilitates access to IVIG therapy: interim results of a hub health program
Authors:Gruenglas J, Carneiro R, Karalian A
Poster presented at: IgNS 2022 11th National Conference; September 29-October 2, 2022; Washington, DC
Pharmacoeconomic analysis comparing medical costs for prophylaxis of HIV and HBV infection in sexual assault patients
Authors:
Gruenglas J, Pantello D, Mond J
Published:
Virtual AMCP 2021 Conference; April 12-16, 2021
Medical Survey Research
Respiratory viral infections continue to be an unresolved problem in the care of immunocompromised transplant patients
Authors:Wetzstein G, Decker D, Mond J
Poster presented at: National Comprehensive Cancer Network 2021 Virtual Annual Conference; March 18-20, 2021
Respiratory viral infections continue to be a growing problem in the care of hematopoietic cell transplanted patients
Authors:Wetzstein G, Decker D, Mond J
Poster presented at: The 2021 Transplantation and Cellular Therapy Meetings Digital Experience; February 8-12, 2021
Respiratory syncytial virus infections continue to be a growing problem in the care of immunocompromised patients receiving transplants
Authors:Wetzstein G, Decker D, Mond J
Poster presented at: International Society for Influenza and Other Respiratory Virus Diseases "RSV Webinar Series"; February 2021